Stock listing
Frankfurt:471A aTyr Pharma, Inc. Aktie
German listing (Frankfurt) of aTyr Pharma, Inc. · home listing NASDAQ:ATYR
Follow aTyr Pharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ATYR
$3.82 USD -0.26 (-6.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ATYR
- Day range
- $3.80 – $4.15 USDNov 20, 2026
- Volume
- 90,514 sharesNov 20, 2026
- Market cap
- $9.74M USDAt the close on Nov 20, 2026 · price × 2.55M shares outstanding
- 52-week range
- $3.80 – $44.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $214,862 USDMedian day 1,131 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ATYR · Home | $3.82 USD | -0.26 (-6.4%) | 90,514 | $3.85 | $4.15 | $3.80 | $4.08 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ATYR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.82 | -0.26 | -6.4% | $3.85 | $4.15 | $3.80 | 90,514 | |
| $4.08 | -0.91 | -18.2% | $4.98 | $5.07 | $4.08 | 117,857 | |
| $4.99 | -0.25 | -4.8% | $5.31 | $5.41 | $4.70 | 125,274 | |
| $5.24 | -0.865 | -14.2% | $5.99 | $6.045 | $5.24 | 38,748 | |
| $6.105 | -0.105 | -1.7% | $6.24 | $6.535 | $5.957 | 38,009 | |
| $6.21 | -0.56 | -8.3% | $6.63 | $6.63 | $6.19 | 35,142 | |
| $6.77 | -0.79 | -10.4% | $7.65 | $7.65 | $6.703 | 46,675 | |
| $7.56 | -0.02 | -0.3% | $7.41 | $7.96 | $7.001 | 113,223 | |
| $7.58 | +1.23 | +19.4% | $6.29 | $7.785 | $5.93 | 185,100 | |
| $6.35 | +0.32 | +5.3% | $5.70 | $6.64 | $5.70 | 69,400 | |
| $6.03 | -0.15 | -2.4% | $6.13 | $6.22 | $5.60 | 59,600 | |
| $6.18 | -0.45 | -6.8% | $6.84 | $6.987 | $5.30 | 152,100 | |
| $6.63 | +0.34 | +5.4% | $6.33 | $7.22 | $6.11 | 229,500 | |
| $6.29 | +1.35 | +27.3% | $5.03 | $6.42 | $5.03 | 334,900 | |
| $4.94 | -0.43 | -8.0% | $5.32 | $5.429 | $4.32 | 120,200 | |
| $5.37 | +0.25 | +4.9% | $4.83 | $5.60 | $4.81 | 227,600 | |
| $5.12 | +0.16 | +3.2% | $4.80 | $5.20 | $4.64 | 85,545 | |
| $4.96 | -1.176 | -19.2% | $4.868 | $5.10 | $4.068 | 5,348 | |
| $6.136 | -0.468 | -7.1% | $6.60 | $6.668 | $5.752 | 2,057 | |
| $6.604 | -0.196 | -2.9% | $6.812 | $6.88 | $6.40 | 813 | |
| $6.80 | -0.092 | -1.3% | $6.80 | $7.184 | $6.72 | 650 | |
| $6.892 | -0.04 | -0.6% | $6.92 | $7.188 | $6.824 | 772 | |
| $6.932 | +0.064 | +0.9% | $6.836 | $7.112 | $6.612 | 826 | |
| $6.868 | -0.092 | -1.3% | $7.196 | $7.36 | $6.60 | 1,319 | |
| $6.96 | -0.392 | -5.3% | $7.56 | $7.644 | $6.96 | 1,137 | |
| $7.352 | +0.02 | +0.3% | $7.60 | $7.88 | $7.352 | 1,391 | |
| $7.332 | -0.712 | -8.9% | $8.00 | $8.288 | $7.228 | 1,608 | |
| $8.044 | -0.548 | -6.4% | $8.80 | $8.80 | $8.00 | 1,654 | |
| $8.592 | -1.256 | -12.8% | $9.908 | $9.996 | $8.592 | 1,266 | |
| $9.848 | -0.364 | -3.6% | $10.21 | $10.36 | $9.84 | 625 | |
| $10.21 | -0.92 | -8.3% | $10.80 | $10.92 | $10.00 | 1,720 | |
| $11.13 | -0.204 | -1.8% | $11.16 | $11.55 | $10.88 | 701 | |
| $11.34 | -0.264 | -2.3% | $11.60 | $11.82 | $11.22 | 639 | |
| $11.60 | +0.112 | +1.0% | $11.33 | $11.76 | $10.60 | 1,131 | |
| $11.49 | -0.276 | -2.3% | $11.49 | $11.84 | $11.26 | 1,238 | |
| $11.76 | -0.356 | -2.9% | $12.20 | $12.41 | $11.60 | 1,372 | |
| $12.12 | -0.188 | -1.5% | $12.33 | $12.80 | $12.00 | 1,127 | |
| $12.31 | +0.40 | +3.4% | $11.67 | $12.72 | $10.88 | 2,408 | |
| $11.91 | -0.292 | -2.4% | $11.74 | $12.64 | $11.66 | 2,583 | |
| $12.20 | -1.304 | -9.7% | $12.37 | $12.66 | $11.28 | 5,225 | |
| $13.50 | -1.504 | -10.0% | $16.17 | $16.30 | $12.96 | 81,325 | |
| $15.01 | +0.752 | +5.3% | $14.40 | $15.20 | $14.00 | 749 | |
| $14.26 | -0.656 | -4.4% | $15.26 | $15.26 | $14.04 | 835 | |
| $14.91 | +0.392 | +2.7% | $15.20 | $15.20 | $14.74 | 574 | |
| $14.52 | -0.54 | -3.6% | $14.80 | $15.52 | $14.40 | 793 | |
| $15.06 | -0.304 | -2.0% | $15.80 | $15.92 | $14.80 | 628 | |
| $15.36 | -0.204 | -1.3% | $15.83 | $15.83 | $15.15 | 596 | |
| $15.57 | +0.024 | +0.2% | $15.76 | $16.03 | $15.00 | 663 | |
| $15.54 | -1.648 | -9.6% | $16.80 | $17.36 | $15.28 | 1,082 | |
| $17.19 | -0.084 | -0.5% | $17.42 | $17.86 | $16.87 | 891 | |
| $17.28 | -0.94 | -5.2% | $18.76 | $18.78 | $17.20 | 577 | |
| $18.22 | -1.016 | -5.3% | $19.20 | $19.44 | $18.02 | 519 | |
| $19.23 | -0.66 | -3.3% | $20.40 | $20.40 | $19.20 | 396 | |
| $19.89 | -0.248 | -1.2% | $19.60 | $20.32 | $19.49 | 159 | |
| $20.14 | +0.42 | +2.1% | $20.20 | $20.36 | $19.20 | 241 | |
| $19.72 | +0.66 | +3.5% | $19.28 | $20.36 | $19.28 | 438 | |
| $19.06 | -2.208 | -10.4% | $21.20 | $21.34 | $19.00 | 733 | |
| $21.27 | -0.332 | -1.5% | $21.60 | $21.72 | $20.04 | 640 | |
| $21.60 | -0.584 | -2.6% | $22.40 | $22.60 | $21.20 | 166 | |
| $22.18 | +0.144 | +0.7% | $22.48 | $22.48 | $21.78 | 184 | |
| $22.04 | -0.76 | -3.3% | $22.90 | $22.90 | $21.24 | 191 | |
| $22.80 | +1.60 | +7.5% | $21.54 | $22.80 | $21.29 | 423 | |
| $21.20 | +1.14 | +5.7% | $20.42 | $21.36 | $19.60 | 431 | |
| $20.06 | -0.06 | -0.3% | $20.40 | $21.36 | $20.01 | 327 | |
| $20.12 | -1.192 | -5.6% | $20.67 | $20.96 | $20.00 | 479 |
Splits
2 splits since 2019 · NASDAQ:ATYR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-40 | Consolidation | |
| 1-for-14 | Consolidation |
- Ticker
- Frankfurt:471A
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
Latest deck · Jun 1, 2026
Investor Presentation (June 2026)
Investor deck · 27 slides
Latest news
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
Nov 19, 2026
Closed $3.82 (-6.4%) on Nov 20, 2026
aTyr Pharma to Participate in Upcoming Investor Conferences
Nov 11, 2026
Closed $6.77 (-10.4%) on Nov 11, 2026
aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
Nov 5, 2026
Closed $6.35 (+5.3%) on Nov 6, 2026
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
Oct 29, 2026
Closed $5.37 (+4.9%) on Oct 29, 2026
aTyr Pharma Announces One-for-40 Reverse Stock Split
Oct 27, 2026
Closed $4.96 (-19.2%) on Oct 27, 2026
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
Oct 19, 2026
Closed $6.87 (-1.3%) on Oct 19, 2026
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Oct 13, 2026
Closed $8.04 (-6.4%) on Oct 13, 2026
ATyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Sep 24, 2026
Closed $13.50 (-10.0%) on Sep 24, 2026
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Sep 1, 2026
Closed $19.72 (+3.5%) on Sep 2, 2026
aTyr Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 170 in all · newest Nov 19, 2026 · oldest 2019
- Decks
- 24 decks · latest Jun 1, 2026
Where aTyr Pharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ATYR · Home listing | NASDAQ | United States | USD |
| gettex:471A | gettex | Germany | EUR |
| Tradegate:471A | Tradegate | Germany | EUR |
| LS Exchange:A2PM86 | LS Exchange | Germany | EUR |
| BOATS:ATYR | BOATS | United States | USD |
| Lang & Schwarz:A2PM86 | Lang & Schwarz | Germany | EUR |
| Frankfurt:471A · This page | Frankfurt | Germany | EUR |
| Hamburg:471A | Hamburg | Germany | EUR |
| Munich:471A | Munich | Germany | EUR |
| Dusseldorf:471A | Dusseldorf | Germany | EUR |
| Stuttgart:471A | Stuttgart | Germany | EUR |
Valuation
Price/book 0.3× against a median of 0.7×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$28.09M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 2.12
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| aTyr Pharma, Inc. · NASDAQ:ATYR | US$9.74M | −US$28.09M | n/a | n/a | n/a | 0.3× | n/a | 0.3× | 2.12 |
| Ceryvyn Therapeutics Limited · ASX:CYV | US$9.96M | −US$9.91M | 0.1× | −14,971× | n/a | 0.5× | n/a | 0.0× | n/a |
| Lisata Therapeutics, Inc. · NASDAQ:LSTA | US$9.71M | −US$273.0M | n/a | −2,730× | n/a | 1.3× | n/a | 0.0× | 0.71 |
| Purple Biotech Ltd. · TASE:PPBT | US$9.70M | US$3.73M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Jasper Therapeutics, Inc. · NASDAQ:JSPR | US$9.64M | −US$125.6M | n/a | −15.7× | n/a | n/a | n/a | n/a | 2.02 |
| Alzinova AB · OMXSTO:ALZ | US$9.58M | US$8.35M | n/a | 17.0× | n/a | 0.6× | −484.4% | 0.0× | n/a |
| Chemomab Therapeutics Ltd. · NASDAQ:CMMB | US$9.58M | US$4.92M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.04 |
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| Median of the others | US$9.58M | US$4.33M | 0.1× | −10.8× | 0.7× | −303.7% | 0.0× | 0.88 |
Forecasts
1 strong buy · 2 buy · 6 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 45.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -23.97 · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sanjay S. Shukla | President and CEO, Director |
| Brandon Yaras | Chief Financial Officer |
| Ashlee Dunston | Investor Relations and Public Affairs |
| Danielle Campbell | VP, Human Resources |
| Leslie Nangle | VP, Research |
| Lisa Carey | VP, Clinical Operations |
Board
| Director | Role |
|---|---|
| Timothy P. Coughlin | Chairman |
| Eric Benevich | Director |
| Jane A. Gross | Director |
| Sanjay S. Shukla | President and CEO, Director |
| Sara L. Zaknoen | Director |
| Svetlana Lucas | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +5.3% |
| Q2 2026 | Aug 7, 2026 | +5.4% |
| Q1 2026 | May 13, 2026 | +5.6% |
| Q4 2025 | Mar 5, 2026 · After close | −8.7% |
| Q3 2025 | Nov 6, 2025 · After close | +6.0% |
| Q2 2025 | Aug 7, 2025 · After close | +1.1% |
| Q1 2025 | May 7, 2025 · After close | +5.7% |
| Q4 2024 | Mar 12, 2025 · Before open | +15.6% |
| Q3 2024 | Nov 7, 2024 · After close | +0.7% |
| Q2 2024 | Aug 13, 2024 · After close | +6.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | +0.6% |
| Q4 2023 | Mar 14, 2024 · After close | +22.8% |
| Q3 2023 | Nov 9, 2023 · After close | −2.6% |
| Q2 2023 | Aug 9, 2023 · After close | 0.0% |
| Q1 2023 | May 9, 2023 · After close | +6.1% |
| Q4 2022 | Mar 9, 2023 | −8.7% |
| Q3 2022 | Nov 10, 2022 · After close | +4.6% |
| Q2 2022 | Aug 15, 2022 · After close | +14.0% |
| Q1 2022 | May 9, 2022 · After close | −3.1% |
| Q4 2021 | Mar 14, 2022 | −9.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2026) | Investor deck | 27 slides | Jun 1, 2026 |
| Corporate Update (May 2026) | Corporate update | 12 slides | May 11, 2026 |
| Technical Presentation (September 2025) | Technical | 11 slides | Sep 15, 2025 |
| European Respiratory Society (ERS) Congress 2025 | Conference | 15 slides | September 2025 |
| Investor Presentation (September 2023) | Investor deck | 21 slides | Sep 26, 2023 |
| Technical Presentation (May 2022) | Technical | 32 slides | May 17, 2022 |
| Technical Presentation (September 2021) | Technical | 13 slides | Sep 13, 2021 |
| European Respiratory Society International Congress 2021 | Conference | 14 slides | Sep 7, 2021 |
| Investor Presentation (January 2021) | Investor deck | 32 slides | Jan 11, 2021 |
| Investor Presentation (May 2020) | Investor deck | 31 slides | May 18, 2020 |
All 24 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2019) | Investor deck | 23 slides | Mar 11, 2019 |
| Investor Presentation (June 2018) | Investor deck | 23 slides | Jun 4, 2018 |
| Investor Presentation (January 2018) | Investor deck | 18 slides | Jan 8, 2018 |
| Investor Presentation (August 2017) | Investor deck | 33 slides | Aug 28, 2017 |
| American Thoracic Society International Conference 2017 | Conference | 55 slides | May 23, 2017 |
| American Academy of Neurology 2017 | Conference | 32 slides | Apr 24, 2017 |
| Technical Presentation (April 2017) | Technical | 6 slides | Apr 24, 2017 |
| Investor Presentation (January 2017) | Investor deck | 37 slides | Jan 9, 2017 |
| Technical Presentation (December 2016) | Technical | 49 slides | Dec 13, 2016 |
| Technical Presentation (December 2016) | Technical | 18 slides | Dec 13, 2016 |
| Investor Presentation (November 2016) | Investor deck | 39 slides | Nov 7, 2016 |
| Corporate Update (May 2016) | Corporate update | 42 slides | May 11, 2016 |
| Investor Presentation (April 2016) | Investor deck | 43 slides | Apr 13, 2016 |
| Investor Presentation (January 2016) | Investor deck | 35 slides | Jan 11, 2016 |
IPO
Priced at US$14.00 a share on May 6, 2015.
- Price
- US$14.00 a share
- Shares offered
- 5,360,000 shares of common stock
- Offering size
- US$75 million
- Underwriters
- J.P. Morgan, Citigroup, BMO Capital Markets, William Blair · In the order on the cover
- Shares delivered
- On or about May 12, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 22, 2014 |
| Filed publicly | Apr 6, 2015 |
| Amended 3 times | Newest May 6, 2015 |
| Shares registered with an exchange | May 6, 2015 |
| Declared effective by the SEC | May 6, 2015 |
| Final prospectus, with the price | May 7, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 7, 2015 |
| EFFECT · Notice that a registration is effective | May 6, 2015 |
| CERTNAS · Nasdaq's certificate of listing | May 6, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | May 6, 2015 |
| S-1/A · Registration statement, amended | May 6, 2015 |
| CORRESP · Letter to the SEC | May 5, 2015 |
| CORRESP · Letter to the SEC | May 4, 2015 |
| CORRESP · Letter to the SEC | May 4, 2015 |
| UPLOAD · Letter from the SEC | May 4, 2015 |
| S-1/A · Registration statement, amended | May 1, 2015 |
All 20 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Apr 27, 2015 |
| CORRESP · Letter to the SEC | Apr 17, 2015 |
| CORRESP · Letter to the SEC | Apr 6, 2015 |
| S-1 · Registration statement | Apr 6, 2015 |
| UPLOAD · Letter from the SEC | Feb 18, 2015 |
| DRSLTR · Letter to the SEC with a draft | Feb 2, 2015 |
| DRS/A · Draft registration statement, amended | Feb 2, 2015 |
| UPLOAD · Letter from the SEC | Jan 21, 2015 |
| DRSLTR · Letter to the SEC with a draft | Dec 22, 2014 |
| DRS · Draft registration statement | Dec 22, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed May 7, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 190.0K | 235.0K | 353.0K | 10.4M | 0 | 10.5M | 422.0K | |||
| Cost of revenue | 1.55M | 1.54M | 2.74M | 1.70M | 1.30M | 17.3M | 14.0M | 746.0K | 713.0K | 900.0K |
| Gross profit | -1.36M | 235.0K | 353.0K | 8.69M | -1.30M | -6.84M | -13.6M | -746.0K | -713.0K | -900.0K |
| Research and development | 60.2M | 54.4M | 42.3M | 42.8M | 23.3M | 17.3M | 14.0M | 20.4M | 30.1M | 42.8M |
| Selling, general and administrative | 17.6M | 13.8M | 13.0M | 14.0M | 10.8M | 9.07M | 9.35M | |||
| Operating income | -77.6M | -67.9M | -54.9M | -46.4M | -34.0M | -15.9M | -23.0M | -32.8M | -47.1M | -57.9M |
| Depreciation and amortization | 664.0K | 708.0K | 592.0K | 232.0K | 475.0K | 569.0K | 635.0K | 746.0K | 713.0K | 900.0K |
| EBITDA | -77.0M | -67.2M | -54.3M | -46.2M | -33.5M | -15.3M | -22.3M | -32.1M | -46.4M | -57.0M |
| Income before tax | -74.1M | -64.0M | -50.4M | -45.3M | -33.8M | -16.2M | -23.8M | -34.5M | -48.2M | -57.9M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -49.0K | |
| Net income | -74.1M | -64.0M | -50.4M | -45.3M | -33.8M | -16.2M | -16.2M | -34.5M | -48.2M | -57.9M |
| Earnings per share, basic | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 | -16.11 | -26.13 | -2.44 |
| Earnings per share, diluted | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 | -16.11 | -26.13 | -2.44 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.7M | 11.1M | 22.5M | 9.98M | 2.34M | 17.0M | 9.21M | 23.0M | 21.1M | 38.4M |
| Short-term investments | 67.9M | 61.1M | 75.6M | 56.2M | 105.6M | 14.7M | 21.9M | 26.6M | 64.0M | 33.8M |
| Receivables | 873.0K | 1.74M | 2.44M | 11.8M | 435.0K | 2.04M | 100.0K | |||
| Current assets | 80.2M | 82.0M | 103.0M | 80.9M | 113.6M | 35.5M | 31.9M | 50.8M | 87.0M | 74.8M |
| Property, plant and equipment | 4.26M | 4.85M | 5.53M | 3.06M | 543.0K | 899.0K | 1.27M | 1.85M | 2.28M | 1.42M |
| Total assets | 93.0M | 96.8M | 120.7M | 95.8M | 115.5M | 38.7M | 36.2M | 52.7M | 89.4M | 80.5M |
| Accounts payable | 3.89M | 4.32M | 3.53M | 3.11M | 1.03M | 1.43M | 847.0K | 1.04M | 2.28M | 2.61M |
| Current liabilities | 15.1M | 15.0M | 16.4M | 13.9M | 6.01M | 5.86M | 12.9M | 10.8M | 10.4M | 8.53M |
| Long-term debt | 8.26M | 14.7M | 9.20M | |||||||
| Total debt | 12.0M | 13.3M | 15.1M | 11.5M | 1.38M | 2.24M | 8.74M | 16.0M | 19.7M | 9.54M |
| Total liabilities | 26.9M | 27.0M | 30.2M | 24.5M | 6.41M | 7.24M | 15.2M | 19.1M | 25.1M | 17.7M |
| Shareholders' equity | 67.5M | 70.0M | 90.7M | 71.5M | 109.3M | 31.6M | 21.2M | 33.6M | 64.2M | 62.8M |
| Shares outstanding | 2.45M | 84.0M | 63.3M | 29.5M | 27.8M | 11.0M | 3.89M | 2.19M | 29.8M | 23.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -62.0M | -69.1M | -33.2M | -41.9M | -33.1M | -15.3M | -20.0M | -31.1M | -42.4M | -52.9M |
| Capital spending | -77.0K | -65.0K | -4.21M | -1.64M | -192.0K | -202.0K | -79.0K | -594.0K | -1.31M | -600.0K |
| Free cash flow | -62.1M | -69.2M | -37.4M | -43.5M | -33.3M | -15.5M | -20.1M | -31.7M | -43.7M | -53.5M |
| Cash from investing | -5.05M | 17.2M | -20.1M | 47.2M | -91.6M | 6.90M | 4.92M | 37.2M | -27.6M | 33.5M |
| Cash from financing | 66.0M | 39.9M | 66.2M | 5.45M | 110.0M | 16.1M | 1.34M | -4.24M | 52.7M | 4.70M |
| Change in cash | -1.03M | -12.0M | 12.9M | 10.8M | -14.6M | 7.74M | -13.8M | 1.87M | -17.3M | -14.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 424B5 · Prospectus | Nov 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 27, 2026 | Current report | SEC |
| 8-K · Current report | Oct 16, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Oct 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 24, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Sep 11, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 31, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 31, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Mar 26, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 26, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Mar 26, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 12, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 15, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 19, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2025 | Other filings | SEC |
| 8-K/A · Current report, amended | Aug 7, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2025 | Offer document | SEC |
| S-3 · Registration statement | Aug 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 8-K · Current report | May 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 19, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 19, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 19, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Dec 23, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2024 | Material contract | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 15, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 7, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 22, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jun 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 18, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 2, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 5, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 5, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 5, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Mar 14, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jan 2, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Nov 21, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 16, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 15, 2023 | Other filings | SEC |
| 4 · Change in ownership | Nov 13, 2023 | Insider trade | SEC |
| S-3 · Registration statement | Nov 9, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Nov 9, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Sep 26, 2023 | Current report | SEC |
| 8-K · Current report | Sep 11, 2023 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 10, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 8-K · Current report | May 19, 2023 | Management or board change | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2023 | Results | SEC |
| 4 · Change in ownership | Apr 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2023 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 18, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 29, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Mar 29, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 29, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Mar 14, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 8-K · Current report | Mar 9, 2023 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Mar 7, 2023 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Feb 22, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 17, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 9, 2023 | Current report | SEC |
| 424B5 · Prospectus | Feb 9, 2023 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 8, 2023 | Offer document | SEC |
| 4 · Change in ownership | Feb 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 6, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 21, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 15, 2022 | Results | SEC |
| 8-K · Current report | Aug 11, 2022 | Current report | SEC |
| 4 · Change in ownership | Jul 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2022 | Insider trade | SEC |
| 8-K · Current report | May 17, 2022 | Current report | SEC |
| 8-K · Current report | May 16, 2022 | Material contract | SEC |
| S-8 · Registration statement for employee plans | May 11, 2022 | Offer document | SEC |
This page holds 200 of 756 filings. Open Filings
Cap table
Built by 6ix from aTyr Pharma, Inc.’s releases
- Common shares
- 2,549,230
- Fully diluted
- 2,549,230
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,549,230 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,549,230 |
| Oct 27, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kathryn Falberg Other companies: Nuvation Bio Inc. (Board of Directors · Since at least Feb 10, 2021); Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Jazz Pharmaceuticals plc (EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Oruka Therapeutics, Inc. (CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past) | Director · May 6, 2015 – May 24, 2016 · Past |
| Amir Nashat Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Morphic Holding Inc (Director · Jun 26, 2019 – Aug 16, 2024 · Past); Scholar Rock Holding Corporation (Director · May 23, 2018 – May 9, 2024 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 1, 2022 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 14, 2019 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Jul 31, 2019 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 9, 2015 · Past); Receptos Inc (Director · May 8, 2013 – Jun 3, 2014 · Past) | Director · May 6, 2015 – May 15, 2018 · Past |
| James C Blair Other companies: Clovis Oncology Inc (Director · Nov 15, 2011 – Jun 10, 2021 · Past); Zogenix Inc (Director · Nov 22, 2010 – May 21, 2014 · Past); Cadence Pharmaceuticals Inc (Director · Oct 24, 2006 – Mar 19, 2014 · Past); Volcano Corp (Director · Jun 14, 2006 – Apr 24, 2008 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Jun 6, 2007 · Past); Pharmion Corp (Director · May 1, 2006 – Mar 7, 2008 · Past); NuVasive Inc (Director · Mar 3, 2006 – May 24, 2007 · Past) | Director · May 6, 2015 – May 8, 2019 · Past |
| Jeffrey S. Hatfield Other companies: Vir Biotechnology, Inc. (Chair of the Board · Since at least Dec 9, 2020); Larimar Therapeutics, Inc. (Chief Executive Officer, Director · Oct 9, 2017 – Jan 22, 2019 · Past); Viridian Therapeutics, Inc. (Director · Aug 10, 2017 – Feb 4, 2021 · Past); InVivo Therapeutics Holdings Corp (Director · Nov 1, 2016 – Jan 19, 2018 · Past); Vitae Pharmaceuticals Inc (Chief Executive Officer, Director · Sep 24, 2014 – Oct 24, 2016 · Past); Ambit Biosciences Corp (Director · Jun 2, 2014 – Nov 10, 2014 · Past) | Director · Apr 3, 2017 – May 6, 2020 · Past |
| Mark Alan Goldberg Other companies: Blueprint Medicines Corp (Director · Since at least Jun 25, 2015); Audentes Therapeutics Inc (Director · Dec 11, 2017 – Jan 15, 2020 · Past); Crescent Biopharma, Inc. (Director · Jul 8, 2014 – May 1, 2024 · Past); Aceragen Inc. (Director · Jan 7, 2014 – Jun 23, 2022 · Past); ImmunoGen Inc (Director · Nov 8, 2011 – Feb 12, 2024 · Past); Synageva BioPharma Corp (EVP, Medical & Reg. Strategy · Nov 2, 2011 – Sep 19, 2014 · Past) | Director · May 6, 2015 – May 9, 2017 · Past |
| John K Clarke Other companies: Verastem, Inc. (Director · Jan 26, 2012 – Jun 12, 2013 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – May 29, 2007 · Past); Momenta Pharmaceuticals Inc (Director · Jun 15, 2006 – Jun 10, 2015 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2006 – Jun 20, 2018 · Past); Visicu Inc (Director · Apr 4, 2006 – Feb 20, 2008 · Past) | Director · May 6, 2015 – May 22, 2024 · Past |
| Paul Schimmel Other companies: Alnylam Pharmaceuticals, Inc. (Co-founder and member of the Board of Directors · Since at least Jan 31, 2006); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – Nov 30, 2007 · Past); Repligen Corporation (Director · Aug 11, 2006 – Jun 14, 2007 · Past); Alkermes plc (Director · Mar 2, 2006 – Jun 15, 2007 · Past) | Director · Since at least May 6, 2015 |
| Timothy P. Coughlin Other companies: Vir Biotechnology, Inc. (Director · Since Jun 9, 2026); ADC Therapeutics SA (Director · Since at least Jun 3, 2025); Travere Therapeutics, Inc. (Director · Since at least Mar 31, 2015); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Jun 7, 2024 · Past); Neurocrine Biosciences, Inc. (Chief Financial Officer · Sep 18, 2006 – Feb 6, 2017 · Past) | Chairman · Since at least Apr 7, 2017 |
| Jill Marie Broadfoot Other companies: Cue Biopharma, Inc. (Director · Since at least Jun 4, 2025); Talphera, Inc. (Director · Since at least Nov 20, 2021); Otonomy Inc (Director · Aug 18, 2021 – Jun 21, 2022 · Past); Vical Incorporated (Sr Vice President, CFO, Sec · Jan 7, 2011 – Apr 1, 2013 · Past) | Chief Financial Officer · Since at least Jul 30, 2018 |
| John Mendlein Other companies: Fate Therapeutics, Inc. (Director · Since at least Sep 30, 2013); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past); Moderna, Inc. (See Remarks · Dec 7, 2018 – Dec 7, 2018 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Jun 15, 2017 · Past) | Director · May 6, 2015 – May 8, 2019 · Past |
All 29 people
| Person | Seat |
|---|---|
| Jane A. Gross Other companies: BriaCell Therapeutics Corp (Director of the Board · Since at least Aug 1, 2022); Aptevo Therapeutics Inc. (SVP & Chief Scientific Officer · Sep 1, 2016 – Jan 29, 2021 · Past) | Director · Since at least Jun 28, 2019 |
| Svetlana Lucas Other companies: Scribe Therapeutics Inc. (Chief Business Officer · Since at least Mar 13, 2026); Jasper Therapeutics, Inc. (Board Member · Since at least Jun 18, 2024) | Director · Since at least Jun 28, 2019 |
| Eric Benevich Other companies: Neurocrine Biosciences, Inc. (Chief Commercial Officer · Since at least May 26, 2015) | Director · Since at least Dec 10, 2024 |
| John T Blake Other companies: Vivani Medical, Inc. (Chief Financial Officer · Mar 26, 2018 – Feb 19, 2020 · Past) | Senior Vice President, Finance · Oct 28, 2015 – Feb 6, 2018 · Past |
| Kelly Blackburn Other companies: CervoMed Inc. (Executive Vice President, Clinical Development · Since at least Aug 16, 2023) | VP, Clinical Affairs · May 6, 2015 – Mar 28, 2016 · Past |
| Andrew Cubitt | VP, Product Protection · May 6, 2015 – Sep 13, 2016 · Past |
| Ashlee Dunston | Investor Relations and Public Affairs · Since at least Oct 29, 2026 |
| Brandon Yaras | Chief Financial Officer · Since at least Aug 10, 2026 |
| Danielle Campbell | VP, Human Resources · Since at least Nov 5, 2026 |
| David John King | Chief Scientific Officer · Sep 21, 2016 – Feb 6, 2018 · Past |
| Fred Ramsdell | VP, Immunology · May 6, 2015 – Oct 1, 2015 · Past |
| Leslie Nangle | VP, Research · Since at least Oct 13, 2026 |
| Lisa Carey | VP, Clinical Operations · Since at least Sep 30, 2025 |
| Melissa A Ashlock | See Remarks · May 6, 2015 – Jan 27, 2016 · Past |
| Nancy Denyes | General Counsel · Since at least Jan 5, 2024 |
| Sanjay S. Shukla | President and CEO, Director · Since at least Mar 30, 2016 |
| Sanuj K Ravindran | Chief Business Officer · Jan 4, 2016 – Feb 7, 2017 · Past |
| Sara L. Zaknoen | Director · Since at least May 21, 2021 |
| Stan Blackburn | Acting Chief Financial Officer · May 6, 2015 – Jan 27, 2016 · Past |
Log in to ask 6ix AI your own questions about aTyr Pharma, Inc.